AIM ImmunoTech Unveils New UPMC Abstract on Finished Clinical Trial Highlighting Ampligen's Synergistic Effects in Treating Advanced Recurrent Ovarian Cancer

Clinical Study Results: AIM ImmunoTech presented data from a Phase 2 clinical study on advanced recurrent ovarian cancer, showing a 50% objective response rate with the combination of Ampligen, cisplatin, and pembrolizumab, compared to much lower rates in previous studies.

Synergistic Potential of Ampligen: The study supports AIM's belief that Ampligen can enhance the effectiveness of checkpoint inhibitors, potentially benefiting patients with refractory cancers that do not respond to standard treatments.

Patents and Intellectual Property: AIM holds several patents related to the use of Ampligen in combination with checkpoint inhibitors for cancer treatment, with expiration dates extending into 2039.

Company Overview: AIM ImmunoTech is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, with Ampligen as its lead investigational drug.